Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Limited announced an investor webinar to discuss its recent achievements and future milestones, including record sales of its OncoSil™ device and plans to expand its geographic footprint, particularly targeting the US market. The webinar will also cover the company’s ongoing studies demonstrating the device’s superior outcomes, a new clinical study in Germany, and the allocation of funds from a recent capital raise. This announcement highlights OncoSil’s strategic efforts to strengthen its market position and enhance its operational capabilities, potentially benefiting stakeholders through expanded market reach and improved treatment outcomes.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the targeted intratumoural placement of Phosphorous-32 (32P) Microparticles alongside chemotherapy. Its flagship product, the OncoSil™ device, is designed for treating unresectable locally advanced pancreatic cancer, offering a targeted radiation approach that minimizes damage to surrounding organs. The device has received CE Marking approval and is recognized as a breakthrough device in Europe and the United States, with commercial availability in over 30 countries.
Average Trading Volume: 52,724
Technical Sentiment Signal: Sell
Current Market Cap: A$20.52M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.